Wellgistics Health Inc. announced an expansion of its agreement with Tollo Health to distribute a GLP-1 companion muscle loss medical food to over 6,500 independent pharmacies and physicians. The product, a branded version of a proprietary formulation, is intended as an adjunct to GLP-1 therapies to help mitigate muscle loss during weight loss and after discontinuation of therapy. Additionally, Wellgistics Health expanded its antiviral offerings by adding the 3CL protease inhibitor supplement Tollovid® to its distribution agreement, alongside the galectin 1 & 3 inhibitor medical food Galectovid®, targeting patients with Long COVID.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Wellgistics Health Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1102511) on November 14, 2025, and is solely responsible for the information contained therein.